HAE Stock Analysis: Haemonetics | NYSE
Medical Devices | NYSE, USA | Market Cap: 3.403m USD | 12M Return: -2.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 62.7M
EPS Trend: 98.9%
Qual. Beats: 0
Rev. Trend: 68.8%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Haemonetics Corporation is a U.S.-based medical technology company headquartered in Boston, Massachusetts, founded in 1971. It operates three business segments - Plasma, Blood Center, and Hospital - serving hospitals, blood collectors, and plasma fractionators. The company sells through a direct sales force and independent distributors, consistent with the standard medical-device B2B model in the healthcare supplies sub-industry.
The Plasma segment supplies automated plasmapheresis systems (such as NexSys PCS) and donor management software to plasma collection centers, while the Blood Center segment offers donor management and blood center workflow tools. The Hospital segment provides a broader clinical portfolio, including viscoelastic hemostasis analyzers (TEG 6s), autologous blood recovery systems (Cell Saver Elite+), vascular closure devices (VASCADE family), and guidewire/sensor products used in electrophysiology and structural heart procedures (SavvyWire, OptoWire).
Haemonetics revenue mix typically combines capital equipment sales with recurring consumables, disposables, and software, giving the business a partial razor-and-blade structure tied to procedure volumes and plasma collections.
- Plasma segment revenue grows on rising immunoglobulin demand and donor center expansion
- Hospital margins expand with TEG 6s hemostasis and VASCADE vascular closure adoption
- OpSens acquisition accelerates interventional cardiology growth with SavvyWire TAVR platform
| Net Income: 97.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.06 > 1.0 |
| NWC/Revenue: 41.40% < 20% (prev 26.22%; Δ 15.18% < -1%) |
| CFO/TA 0.12 > 3% & CFO 293.2m > Net Income 97.3m |
| Net Debt (986.3m) to EBITDA (280.2m): 3.52 < 3 |
| Current Ratio: 2.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.2m) vs 12m ago -6.57% < -2% |
| Gross Margin: 57.34% > 18% (prev 55.28%; Δ 2.05% > 0.5%) |
| Asset Turnover: 55.05% > 50% (prev 55.52%; Δ -0.48% > 0%) |
| Interest Coverage Ratio: 6.80 > 6 (EBIT TTM 168.5m / Interest Expense TTM 24.8m) |
| A: 0.23 (Total Current Assets 834.9m - Total Current Liabilities 282.6m) / Total Assets 2.40b |
| B: 0.12 (Retained Earnings 279.3m / Total Assets 2.40b) |
| C: 0.07 (EBIT TTM 168.5m / Avg Total Assets 2.42b) |
| D: 0.50 (Book Value of Equity 796.3m / Total Liabilities 1.60b) |
| Altman-Z'' = 2.88 = A |
| DSRI: 1.09 (Receivables 216.9m/202.7m, Revenue 1.33b/1.36b) |
| GMI: 0.96 (GM 55.28% / 57.34%) |
| AQI: 1.04 (AQ_t 0.52 / AQ_t-1 0.50) |
| SGI: 0.98 (Revenue 1.33b / 1.36b) |
| TATA: -0.08 (NI 97.3m - CFO 293.2m) / TA 2.40b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 76.19 with a total of 456,251 shares traded. Over the past week, the price has changed by +1.49%, over one month by -3.31%, over three months by +32.92% and over the past year by -2.53%.
Current recommended Stop Loss: 70.00 (which is 8.1% or 2.1 ATR below the current price).
Haemonetics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy HAE.
- StrongBuy: 3
- Buy: 5
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 85.2 | 11.8% |
P/E Trailing = 36.7059
P/E Forward = 14.3885
P/S = 2.5509
P/B = 4.2842
P/EG = 1.1984
Revenue TTM = 1.33b USD
EBIT TTM = 168.5m USD
EBITDA TTM = 280.2m USD
Long Term Debt = 1.22b USD (from longTermDebt, last quarter)
Short Term Debt = 5.01m USD (from shortTermDebt, last quarter)
Debt = 1.23b USD (from shortLongTermDebtTotal, last quarter) + Leases 7.20m
Net Debt = 986.3m USD (calculated: Debt 1.23b - CCE 245.4m)
Enterprise Value = 4.39b USD (3.40b + Debt 1.23b - CCE 245.4m)
Interest Coverage Ratio = 6.80 (Ebit TTM 168.5m / Interest Expense TTM 24.8m)
EV/FCF = 16.85x (Enterprise Value 4.39b / FCF TTM 260.4m)
FCF Yield = 5.93% (FCF TTM 260.4m / Enterprise Value 4.39b)
FCF Margin = 19.52% (FCF TTM 260.4m / Revenue TTM 1.33b)
Net Margin = 7.29% (Net Income TTM 97.3m / Revenue TTM 1.33b)
Gross Margin = 57.34% ((Revenue TTM 1.33b - Cost of Revenue TTM 569.1m) / Revenue TTM)
Gross Margin QoQ = 57.23% (prev 56.47%)
Tobins Q-Ratio = 1.83 (Enterprise Value 4.39b / Total Assets 2.40b)
Interest Expense / Debt = 2.01% (Interest Expense 24.8m / Debt 1.23b)
Taxrate = 24.00% (30.7m / 128.0m)
NOPAT = 128.1m (EBIT 168.5m * (1 - 24.00%))
Current Ratio = 2.95 (Total Current Assets 834.9m / Total Current Liabilities 282.6m)
Debt / Equity = 1.55 (Debt 1.23b / totalStockholderEquity, last quarter 796.3m)
Debt / EBITDA = 3.52 (Net Debt 986.3m / EBITDA 280.2m)
Debt / FCF = 3.79 (Net Debt 986.3m / FCF TTM 260.4m)
Total Stockholder Equity = 859.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.02% (Net Income 97.3m / Total Assets 2.40b)
RoE = 11.32% (Net Income TTM 97.3m / Total Stockholder Equity 859.8m)
RoCE = 8.10% (EBIT 168.5m / Capital Employed (Equity 859.8m + L.T.Debt 1.22b))
RoIC = 6.24% (NOPAT 128.1m / Invested Capital 2.05b)
WACC = 5.37% (E(3.40b)/V(4.63b) * Re(6.76%) + D(1.23b)/V(4.63b) * Rd(2.01%) * (1-Tc(0.24)))
Discount Rate = 6.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -4.64%
[DCF] Terminal Value 77.97% ; FCFF base≈213.2m ; Y1≈244.4m ; Y5≈359.8m
[DCF] Fair Price = 97.42 (EV 5.41b - Net Debt 986.3m = Equity 4.43b / Shares 45.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.89 | EPS CAGR: 13.91% | SUE: 0.39 | # QB: 0
Revenue Correlation: 68.77 | Revenue CAGR: 2.94% | SUE: 1.20 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.09 | Chg30d=-1.40% | Revisions=-25% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.28 | Chg30d=+0.00% | Revisions=+0% | Analysts=11
EPS current Year (2027-03-31): EPS=5.22 | Chg30d=-0.03% | Revisions=-25% | GrowthEPS=+5.2% | GrowthRev=+5.0%
EPS next Year (2028-03-31): EPS=5.76 | Chg30d=-0.13% | Revisions=-25% | GrowthEPS=+10.3% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: -38% (up=1, down=4)